%PDF-1.4
%
26 0 obj
<>
endobj
23 0 obj
<>
endobj
75 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-07-09T09:31:47Z
2024-03-28T18:43:44-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T18:43:44-07:00
application/pdf
Heather
2003-316.aug
uuid:2738ede9-1dd2-11b2-0a00-0f09275d6100
uuid:2738eded-1dd2-11b2-0a00-aa0000000000
endstream
endobj
12 0 obj
<>
endobj
13 0 obj
<>
endobj
27 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 4 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 6 0 R/Type/Page>>
endobj
81 0 obj
[85 0 R]
endobj
82 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.17841 Tw 10 0 0 10 54 713.1616 Tm
[(the university)64.8 (. But the university went further)39.7 (, instituting)]TJ
-0.00929 Tw 0 -1.2 TD
(strict guidelines for clinical research)Tj
0 Tc 0 Tw 6.5 0 0 6.5 199.1022 704.4616 Tm
(9)Tj
-0.00011 Tc -0.00929 Tw 10 0 0 10 204.7593 701.1616 Tm
(that explicitly prohibit)Tj
0.20979 Tw -15.0759 -1.2 Td
(faculty from participating in clinical research if they \(or)Tj
0.00549 Tc 0.3694 Tw T*
(members of their family\) have any material financial)Tj
-0.00011 Tc 0.0105 Tw T*
(interest in a private company whose product they are evalu-)Tj
T*
[(ating. Harvard has recently followed suit. )17.7 (The University of)]TJ
0.0296 Tw T*
[(T)69.9 (oronto, following the fiasco)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 171.375 644.4615 Tm
(10)Tj
-0.00011 Tc 0.0296 Tw 10 0 0 10 180.671 641.1616 Tm
(involving contracts between)Tj
-0.0159 Tw -12.6671 -1.2 Td
[(researchers Nancy Olivieri and Gideon Koren and )54.8 (Apotex, a)]TJ
0.18089 Tw T*
(pharmaceutical firm, are revising their policies)Tj
0 Tc 0 Tw 6.5 0 0 6.5 250.1708 620.4615 Tm
[(1)56.7 (1,12)]TJ
-0.00011 Tc 0.18089 Tw 10 0 0 10 264.427 617.1616 Tm
(. Other)Tj
0.2049 Tw -21.0427 -1.2 Td
[(Canadian universities will undoubtedly follow)64.8 (. )17.7 (There are)]TJ
0.0601 Tw T*
(calls for even stricter reforms and for regulation of clinical)Tj
0.02499 Tw T*
(research funding)Tj
0 Tc 0 Tw 6.5 0 0 6.5 121.1543 584.4615 Tm
(13)Tj
10 0 0 10 127.6542 581.1616 Tm
(.)Tj
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw -7.3654 -2.4 Td
[(CONTINUING PROFESSIONAL)-220.2 (DEVELOPMENT)]TJ
/T1_0 1 Tf
0.0163 Tw T*
(Probably most readers of this journal have been involved in)Tj
0.3517 Tw T*
(CME, whether as pharmaceutical company consultants,)Tj
0.05721 Tw T*
(course leaders, speakers, or participants. CME is necessary)Tj
0.0807 Tw T*
(and expensive, so it is understandable that physicians look)Tj
-0.00661 Tw T*
(for financial support for tuition, travel, and accommodation.)Tj
0.049 Tw T*
(And it is equally understandable that pharmaceutical firms,)Tj
0.103 Tw T*
(eager to convince physicians of the benefits of their prod-)Tj
0.0488 Tw T*
[(ucts, like to \322help out\323 by paying these costs. Recently)64.8 (, the)]TJ
0.02969 Tw T*
(Canadian \322Rx&D\323 pharmaceutical firms have succeeded in)Tj
0.1479 Tw T*
(persuading the Royal Colleges and the Canadian Medical)Tj
0.23 Tw T*
(Association to weaken their stance on CME funding by)Tj
0.02361 Tw T*
(pharmaceutical companies)Tj
0 Tw 6.5 0 0 6.5 160.569 416.4616 Tm
(14-16)Tj
0.02361 Tw 10 0 0 10 175.7318 413.1616 Tm
[(. However)39.7 (, both the literature)]TJ
-0.02679 Tw -12.1732 -1.2 Td
(on the influence of money on professional behavior in medi-)Tj
0.1523 Tw T*
(cine and the public perception of gifts and incentives are)Tj
0.09261 Tw T*
[(decidedly negative. In my view)64.8 (, this recent ethical wobble)]TJ
0.0112 Tw T*
(by the physician associations is damaging to the profession.)Tj
0.05589 Tw 1.2 -1.2 Td
(I would venture to say that medical journal editors have)Tj
0.1123 Tw -1.2 -1.2 Td
(been slow to tackle ethical issues in research, publication,)Tj
0.14391 Tw T*
[(and continuing professional development. )54.8 (A)-339 (search of the)]TJ
0.1964 Tw T*
[(almost 1)36.7 (1,000 )]TJ
/T1_2 1 Tf
0.1965 Tw 6.2723 0 Td
(Journal of Rheumatology )Tj
/T1_0 1 Tf
0.1964 Tw 11.0039 0 Td
(articles listed in)Tj
0.0163 Tw -17.2763 -1.2 Td
(PubMed since 1971 revealed only 6 coded under the MeSH)Tj
0.1767 Tw T*
[(Major )17.7 (T)69.9 (opic heading of \322ethics\323)]TJ
0 Tw 6.5 0 0 6.5 190.1343 296.4616 Tm
(17-22)Tj
0.1767 Tw 10 0 0 10 205.2972 293.1616 Tm
(. Granted, this was a)Tj
0.0009 Tw -15.1297 -1.2 Td
(crude search that may have missed some. But I suspect that,)Tj
0.0813 Tw T*
(had I done this search for most specialty medical journals,)Tj
0.02499 Tw T*
(the results would have been equally sparse.)Tj
0.233 Tw 1.2 -1.2 Td
(By writing more about ethical issues in research and)Tj
0.1987 Tw -1.2 -1.2 Td
(publication, by reporting on some of the most egregious)Tj
0.0045 Tw T*
(misconduct, and by encouraging debate in their pages about)Tj
0.02901 Tw T*
(the role of pharmaceutical companies and other sponsors in)Tj
0.3661 Tw T*
(the professional lives of physicians and their patients,)Tj
0.21449 Tw T*
(medical journals can promote more responsible behavior)Tj
-0.0358 Tw T*
(and acquire a cleaner public image. Journals that neglect this)Tj
0.0081 Tw T*
(self-critique and study may risk a more painful examination)Tj
0.02499 Tw T*
(by others.)Tj
/T1_1 1 Tf
7.2 -2.4 Td
(JOHN HOEY)Tj
/T1_0 1 Tf
0 Tc 0 Tw [-0.2 (, )]TJ
-0.00011 Tc 6 0 0 6 191.2217 125.1616 Tm
(MD,)Tj
8 0 0 8 126 115.1616 Tm
[(Editor)39.7 (, )]TJ
0.02499 Tw 0 -1.25 TD
[(CMAJ )17.7 (The Canadian Medical )54.8 (Association Journal,)]TJ
T*
[(1867 )54.8 (Alta )17.7 (V)59.8 (ista Drive, Ottawa, Canada K1G 3Y6)]TJ
/T1_2 1 Tf
-9 -2.5 Td
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equests to Dr)110.7 (. Hoey)54.8 (, E-mail: hoeyj@cma.ca)]TJ
/T1_1 1 Tf
0 Tw 10 0 0 10 318 713.1616 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 325 703.1616 Tm
[(1.)-875.1 (Gordon DA. Medical publication ethics [editorial]. J Rheumatol)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
(2003;30:1851-6.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (Questions of interest [editorial]. CMAJ 2002;166:413.)]TJ
T*
[(3.)-875.1 (Baird P)110.7 (. Getting it right: industry sponsorship and medical research.)]TJ
0 Tc 1.675 -1.25 Td
(CMAJ 2003;168:1267-9.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (Kettler H. Updating the cost of a new chemical entity)64.8 (. London:)]TJ
1.675 -1.25 Td
[(Of)17.7 (fice of Health Economics; 1999. Summary available from:)]TJ
T*
[(http://www)64.8 (.ohe.or)17.7 (g/updating.htm#Updating [accessed )54.8 (April 15,)]TJ
0 Tc 0 Tw T*
(2003].)Tj
-0.00011 Tc 0.0249 Tw -1.675 -1.25 Td
[(5.)-875.1 (Davidof)17.7 (f F)79.7 (, DeAngelis CD, Drazen JM, et al. Sponsorship, )]TJ
1.675 -1.25 Td
[(authorship and accountability)64.8 (. CMAJ 2001;165:786-8.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Look, no strings: publishing industry-funded research [editorial].)]TJ
0 Tc 1.675 -1.25 Td
(CMAJ 2001;165:733.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875.1 (Drug marketing: Unsafe at any dose? [editorial]. CMAJ)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
(2002;167:981.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Sibbald B. Death but one unintended consequence of gene-therapy)]TJ
0 Tc 1.675 -1.25 Td
[(trial.)-89.9 (CMAJ 2001;164:1612.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (University of Pennsylvania. Financial disclosure and forbidden)]TJ
1.675 -1.25 Td
[(conflicts for faculty participating in clinical trials [accessed )54.8 (April)]TJ
T*
[(17, 2003]. )54.8 (A)74 (vailable from: )]TJ
-0.0101 Tc 0 Tw T*
[(http://www)64.8 (.upenn.edu/research/financialdisclosure_clinicaltrials.htm)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Phillips RA, Hoey J. Constraints of interest: lessons at the Hospital)]TJ
2.175 -1.25 Td
(for Sick Children. CMAJ 1998;159:955-7.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Naylor CD, for the Research Committee and Clinical Study)]TJ
2.1381 -1.25 Td
[(Agreements )17.7 (W)79.9 (orking Group of the )17.7 (T)69.9 (oronto )54.8 (Academic Health)]TJ
T*
[(Science Council. Early )17.7 (T)69.9 (oronto experience with new standards for)]TJ
T*
(industry-sponsored clinical research: a progress report [editorial].)Tj
0 Tc T*
(CMAJ 2002;166:453-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875.1 (Naylor CD. Early )17.7 (T)69.9 (oronto experience with new standards for)]TJ
2.175 -1.25 Td
(industry-sponsored clinical research: a progress report. CMAJ)Tj
0 Tc 0 Tw T*
(2002;166:453-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Lewis S, Baird P)110.7 (, Evans RG, et al. Dancing with the porcupine:)]TJ
2.175 -1.25 Td
(rules for governing the university\320industry relationship. CMAJ)Tj
0 Tc 0 Tw T*
(2001;165:783-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875.1 (Y)99.8 (eo M. Marketing R&D: one step forward, two steps back. CMAJ)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(2003;168:1273-4.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Hansen D. CMAJ 2003;168 [in press])]TJ
T*
[(16.)-875.1 (Y)99.8 (eo M. CMAJ 2003;168 [in press])]TJ
T*
[(17.)-875.1 (Hadler NM. Options in disability determination. Lessons that)]TJ
2.175 -1.25 Td
(pertain to the regional musculoskeletal disorders. J Rheumatol)Tj
0 Tc 0 Tw T*
(2002;29:407-10.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (Panush RS. Not for sale, not even for rent: just say no. )17.7 (Thoughts)]TJ
2.175 -1.25 Td
[(about the )54.8 (American College of Rheumatology adopting a code of)]TJ
T*
(ethics. J Rheumatol 2002;29:1049-57.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Laxer RM, Harrison C. Bioethical issues in autologous stem cell)]TJ
2.175 -1.25 Td
(transplantation in children and adults with arthritis. J Rheumatol)Tj
0 Tc 0 Tw T*
(2001;28:2147-50.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (Harrison C, Laxer RM. )54.8 (A)-220.1 (bioethics education program in pediatric)]TJ
2.175 -1.25 Td
[(rheumatology)64.8 (. J Rheumatol 2000;27:1780-2.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Gordon DA. Rheumatoid arthritis \321 new treatments, and a new)]TJ
2.175 -1.25 Td
(look at medical ethics. J Rheumatol 1998;25:2049.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Levine RJ. Postmarketing surveillance \321 some ethical )]TJ
2.175 -1.25 Td
(considerations. J Rheumatol 1988;15 Suppl 17:34-9.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:8)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(1662)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
6 0 obj
<>stream
8;Z\7=a%\:#itt$j>q^K21X&.ADF&-,p0Q/"jII60_<'XgRg74$s1!O0"QSm^'8b_
i7I.4ca)$cQW*+aL%V:^[CrPs`ST4)A,1[O[uoL(:mYkQh_8riX^#Sdr]/')k=_$r
@&Pbdn@;sK8=(R%1/Ka7;/&7u;"$Ds'%$dH.G(0PCa'P>?r_8#bld"-+ih;iW*i
Mq2iM6q7[^^1OSb.lJ4G*,:Wra7F]1E?M;.ah+h/')+.t*CgT`5U'R]?taStUmRD0
_s1GGqV]Yjng.3DD31e#h<^:=;X.3W,+Fdl_)75t?mGD;`V7ZD^2hKB&G%It*"c`&
V*o[EWg)um9qP8,g5H;XCsLZ36)5([CEJBX-5*+;rcl46%'tk('Z[1VpGb@iF98th
0jXW"dR4n:cKQ(kc/F4pEe93tasM2R1d_5/@/pJfDAJ8m)W[iqlT!Tj\3ZVnU\7\4
:@YFKZp%?+qQ(>@*Y*Ii\J!G4%]g\r=ZGXCCdt["/.tI896HC9f_3;$1FCl[
\0et-5A^_Nn6h)26oX]0P9T!B_nqG#g5AqT:bm=*>/[ZYigc\^Z[b(RR3K.![N2ji
?ZJ9^PWe0-Slkr0i3Kt)]S'_r@$u=P>'_0\JbaaaK,9a/[S04nRE/SCFo(p"09Soo
UN-P,-`-P(CX3sP]Y];4J)KBW,M?M7[ortNqPXi#@J^rCq,2;X~>
endstream
endobj
10 0 obj
[/Indexed/DeviceRGB 255 9 0 R]
endobj
9 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
31 0 obj
<>
endobj
35 0 obj
<>
endobj
32 0 obj
<>
endobj
70 0 obj
<>
endobj
80 0 obj
<>
endobj
29 0 obj
<>
endobj
57 0 obj
<>stream
HT{PSgpB*j)[wEDAP\JDIx$&ޏ@H.$ /QZSQauUFWXˌ=~tvv:Sf|sw^Y[a8wŁXdR+x`~dᰳ< Zl9mk
mg5HK/p1R(R5.B&EJq;M
Z.VI;ƴDAh\)1l?+)Ubg3-\*NDJDrX}>[fgsYacql-ưe>ǰ
S0 5UFPgJE`ZjMc|^á
tJ \>5dV5,%&&f7w8
:/3433̯֚/Zѫdp`= FLv&Sׯ*;(TO LTW5ZI~3ឌagO,FCLJMezA>/6 S.D؝]'PA3-:+.pqú+h/X쇆a["$